EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Quantitative Coronary Atherosclerotic Plaque Burden From CCTA and the Benefit From Lipid-Lowering Medication

Teemu Maaniitty iD, Sarah Bär iD, Jeroen J Bax iD, Juhani Knuuti iD, Antti Saraste iD

Circulation: Cardiovascular Imaging · 2026-04 · 19 (4)

DOI: 10.1161/circimaging.125.018840 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Circulation: Cardiovascular Imaging, 2026-04. Verfasst von Teemu Maaniitty und 4 weiteren Autor:innen. Beteiligte Einrichtung: Turku PET Centre, Turku University Hospital and University of Turku, Finland (T.M., S.B., J.K., A.S.). Hauptthemen laut MEDLINE: Plaque, Atherosclerotic, Coronary Artery Disease, Coronary Angiography, Computed Tomography Angiography. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: We hypothesized that quantification of coronary atherosclerotic plaque burden by artificial intelligence-guided quantitative computed tomography can identify patients who derive outcome benefit from lipid-lowering medication (LLM). METHODS: In this observational cohort study, consecutive symptomatic patients undergoing coronary computed tomography angiography for suspected coronary artery disease (CAD) were assessed for percent atheroma volume (PAV) by artificial intelligence-guided quantitative computed tomography. The use of LLM was assessed based on drug purchase registry data within 6 months after coronary computed tomography angiography. Patients were followed for the composite of death, myocardial infarction, and unstable angina for a median of 6.9 years. RESULTS: Among 2269 patients (median age, 63 years; 42% men), 1261 (56%) patients used LLM after coronary computed tomography angiography, and 255 (11%) experienced the composite end point during follow-up. The median PAV was 6.6% among users and 1.4% among nonusers of LLM ( P 5% (annual event rate, 2.62% versus 4.14%; adjusted P =0.002), even in the absence of obstructive CAD, but not among the 1359 patients with PAV ≤5% (annual event rate, 0.94% versus 0.65%; adjusted P =0.717). An adjusted Cox regression analysis, including interaction between PAV and LLM, suggested a PAV threshold between 4% and 10% for gaining prognostic benefit from LLM. CONCLUSIONS: In symptomatic patients with suspected CAD, LLM after coronary computed tomography angiography was associated with a lower rate of adverse events during long-term follow-up among those with PAV >5%, even in the absence of obstructive CAD. The quantification of coronary atherosclerotic plaque burden is a potential marker to guide preventive lipid-lowering therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Plaque, AtheroscleroticCoronary Artery DiseaseCoronary AngiographyComputed Tomography AngiographyCoronary VesselsHypolipidemic AgentsHumansMaleFemaleMiddle AgedPredictive Value of TestsAgedTreatment OutcomeTime FactorsArtificial IntelligenceRisk FactorsRegistriesMyocardial InfarctionSeverity of Illness IndexAngina, Unstable

Stichwörter der Autor:innen

artificial intelligencecoronary artery diseaselipidsmiddle agedprognosis

Substanzen

Hypolipidemic Agents

Autor:innen und Institutionen

  • Turku PET Centre, Turku University Hospital and University of Turku, Finland (T.M., S.B., J.K., A.S.).
  • Department of Clinical Physiology, Nuclear Medicine and PET, Turku University Hospital, Finland (T.M., J.K.).
  • Department of Cardiology, Bern University Hospital Inselspital, Switzerland (S.B.).
  • Department of Cardiology, Leiden University Medical Center, the Netherlands (J.J.B.).
  • Heart Center, Turku University Hospital and University of Turku, Finland (J.J.B., A.S.).
  • Faculty of Medicine, University of Turku, Finland (J.J.B., J.K., A.S.).

ORCID-Profile: Teemu Maaniitty, Sarah Bär, Jeroen J Bax, Juhani Knuuti, Antti Saraste

Zitieren

APA

Maaniitty, T., Bär, S., Bax, J. J., Knuuti, J., & Saraste, A. (2026). Quantitative Coronary Atherosclerotic Plaque Burden From CCTA and the Benefit From Lipid-Lowering Medication. Circulation: Cardiovascular Imaging, 19(4). https://doi.org/10.1161/circimaging.125.018840

Vancouver

Maaniitty T, Bär S, Bax JJ, Knuuti J, Saraste A. Quantitative Coronary Atherosclerotic Plaque Burden From CCTA and the Benefit From Lipid-Lowering Medication. Circulation: Cardiovascular Imaging. 2026;19(4). doi:10.1161/circimaging.125.018840

BibTeX
@article{Maaniitty2026,
  author = {Maaniitty, Teemu and Bär, Sarah and Bax, Jeroen J and Knuuti, Juhani and Saraste, Antti},
  title = {Quantitative Coronary Atherosclerotic Plaque Burden From CCTA and the Benefit From Lipid-Lowering Medication},
  journal = {Circulation: Cardiovascular Imaging},
  year = {2026},
  volume = {19},
  number = {4},
  doi = {10.1161/circimaging.125.018840}
}
Kostenlos starten →